Walfred Tang

Walfred Tang has extensive work experience in scientific research and development. Walfred is currently working at Adrestia Therapeutics as a Principal Scientist since July 2022. Before that, they held the position of Senior Research Scientist at the same company from May 2021 to July 2022. Prior to joining Adrestia Therapeutics, Walfred was a Visiting Researcher at the University of Cambridge starting from May 2021. Walfred also worked as a Postdoctoral Research Associate at the University of Cambridge from March 2016 to April 2021, where they led research projects on epigenetic regulations of human germ cell development and cancer. Walfred has expertise in engineering novel CRISPR epigenome editing systems and direct programming of pluripotent stem cells. In 2008, Walfred had a summer internship at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Walfred also had a temporary trainee role at CK Life Sciences in June and July 2007.

Walfred Tang began their education journey in 2005 and completed their Bachelor of Science degree in Biochemistry at The Chinese University of Hong Kong in 2009. In 2006, they participated in a full-year exchange program at The University of British Columbia, where they focused on Biochemistry. Walfred then pursued their Master of Philosophy degree in Biological and Biomedical Sciences at The Chinese University of Hong Kong from 2009 to 2011. Lastly, Walfred obtained their Doctor of Philosophy degree in Developmental Biology and Embryology from the University of Cambridge, which they completed in 2016.